Summary & Overview

Knee Procedures with Principal Diagnosis of Infection without CC/MCC: Inpatient Reimbursement Overview

DRG 487 covers knee procedures where the principal diagnosis is infection without Complication or Comorbidity or Major Complication or Comorbidity and groups cases by similar resource use for inpatient reimbursement. This classification matters because principal diagnosis selection and documentation of complications or comorbidities determine Medicare payment levels for knee infection admissions.

Knee Procedures with Principal Diagnosis of Infection without CC/MCCDRG Knee Procedures with Principal Diagnosis of Infection without CC/MCCDRG 487Diagnosis-Related GroupInpatient ReimbursementMedicareOrthopedicsInfectious DiseaseJoint Arthroplasty

DRG 487 Overview

DRG 487 covers inpatient cases for knee procedures performed when the principal diagnosis is an infection and there are no Complication or Comorbidity or Major Complication or Comorbidity present. Typical clinical scenarios include debridement, irrigation, and synovectomy for septic arthritis or infected total knee arthroplasty without additional coded complications. This Diagnosis-Related Group groups similar resource use to set a prospective payment amount under Medicare, so accurate coding of the infection as the principal diagnosis and the absence of Complication or Comorbidity or Major Complication or Comorbidity affect reimbursement. Proper assignment influences hospital payment relative to other knee procedure Diagnosis-Related Groups with higher-acuity comorbidity designations.

Clinical Trials

Acute surgical and antimicrobial timing trials: studies investigating optimal timing and sequence of surgical debridement or irrigation and drainage relative to initiation and duration of intravenous antimicrobial therapy for patients admitted with infected knee prostheses or native septic arthritis. These trials enroll inpatients presenting with acute knee infection, often stratified by prosthetic vs native joint involvement and severity at presentation, and measure metrics such as time to infection control, need for repeat operations, length of stay, and in-hospital complications. Findings are highly relevant to surgeons, infectious disease teams, and payers because they can inform protocols that reduce readmissions, lower procedure counts, and shorten costly hospital stays.
Comparative effectiveness studies of surgical approaches and implant management: randomized or observational comparative studies evaluating outcomes of procedures such as one-stage versus two-stage prosthetic knee exchange, debridement with implant retention versus revision, or arthroscopic versus open drainage in native joint infections. These studies focus on subpopulations defined by prosthesis status, organism virulence, and host risk factors (immunosuppression, comorbidities), tracking outcomes like infection eradication, functional recovery, reoperation rates, and total inpatient resources used. Results guide clinicians and payers in selecting resource-intense strategies that balance durable infection control and functional outcomes against cost, length of stay, and likelihood of subsequent hospitalizations.
Post-discharge outcomes and care-pathway studies: prospective cohort or pragmatic trials examining post-hospital transitions such as outpatient parenteral antimicrobial therapy (OPAT) protocols, home health support, and rehabilitation pathways for patients discharged after treatment for knee infection. These studies target typical discharge populations (patients completing long antibiotic courses, those with staged reconstructions, or with post-op wound-care needs) and evaluate readmission rates, catheter-related complications, adherence to therapy, functional status at 90 days, and overall downstream costs. Insights from this research inform discharge planning, utilization of home infusion or skilled nursing services, and payer policies aimed at reducing readmissions and total episode-of-care spending.

Related Codes

504-FOOT-PROCEDURES-WITH-CC

Foot Procedures with CC: Inpatient Reimbursement Overview

495-LOCAL-EXCISION-AND-REMOVAL-OF-INTERNAL-FIXATION-DEVICES-EXCEPT-HIP-AND-FEMUR-WITH-MCC

Local Excision and Removal of Internal Fixation Devices Except Hip and Femur with MCC: Inpatient Reimbursement Overview

547-CONNECTIVE-TISSUE-DISORDERS-WITHOUT-CC-MCC

Connective Tissue Disorders without CC/MCC: Inpatient Reimbursement Overview

514-HAND-OR-WRIST-PROCEDURES-EXCEPT-MAJOR-THUMB-OR-JOINT-PROCEDURES-WITHOUT-CC-MCC

Hand or Wrist Procedures, Except Major Thumb or Joint Procedures without CC/MCC: Inpatient Reimbursement Overview

552-MEDICAL-BACK-PROBLEMS-WITHOUT-MCC

Medical Back Problems without MCC: Inpatient Reimbursement Overview

533-FRACTURES-OF-FEMUR-WITH-MCC

Fractures of Femur with Major Complication or Comorbidity: Inpatient Reimbursement Overview

428-MULTIPLE-LEVEL-COMBINED-ANTERIOR-AND-POSTERIOR-SPINAL-FUSION-EXCEPT-CERVICAL-WITHOUT-CC-MCC

Multiple Level Combined Anterior and Posterior Spinal Fusion Except Cervical without CC/MCC: Inpatient Reimbursement Overview

481-HIP-AND-FEMUR-PROCEDURES-EXCEPT-MAJOR-JOINT-WITH-CC

Hip and Femur Procedures Except Major Joint with CC: Inpatient Reimbursement Overview

463-WOUND-DEBRIDEMENT-AND-SKIN-GRAFT-EXCEPT-HAND-FOR-MUSCULOSKELETAL-AND-CONNECTIVE-TISSUE-DISORDERS-WITH-MCC

Wound Debridement and Skin Graft Except Hand for Musculoskeletal and Connective Tissue Disorders with MCC: Inpatient Reimbursement Overview

472-CERVICAL-SPINAL-FUSION-WITH-CC

Cervical Spinal Fusion with CC: Inpatient Reimbursement Overview

Showing 1–10 of 104

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.